Asterias Biotherapeutics Announces Public Offering of Common Stock

sterias Biotherapeutics, Inc. (NYSE MKT:

) (the "Company"), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it has commenced an underwritten public offering of its common stock. MLV & Co. LLC is acting as the Sole Book-Running Manager for the offering. The offering will be made pursuant to the Company's existing effective shelf registration statement, previously filed with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. The offering of these securities will be made only by means of a prospectus and related prospectus supplement, when available. Before you invest, you should read the prospectus in the registration statement and related prospectus supplements and other documents that the Company has filed with the SEC for more complete information about the Company and this offering. Copies of the prospectus and accompanying preliminary prospectus supplement relating to these securities may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov or by written request to Asterias Biotherapeutics, Inc., 230 Constitution Drive, Menlo Park, CA 94025. Alternatively, copies of the prospectus and accompanying preliminary prospectus supplement relating to these securities may be obtained by contacting MLV & Co. LLC, 1251 Avenue of the Americas, New York, NY 10020, Attention: Randy Billhardt, Email: rbillhardt@mlvco.com; Telephone: (888) 344-2272.